Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors

AIDS

Volumn 20, Issue 2, 2006, Pages 287-289

  Roquebert, Bénédicte ^a,b   Malet, Isabelle ^a,b   Wirden, Marc ^a,b   Tubiana, Roland ^a,c   Valantin, Marc Antoine ^a,c   Simon, Anne ^a   Katlama, Christine ^a,c   Peytavin, Gilles ^d   Calvez, Vincent ^a,b   Marcelin, Anne Geneviève ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; GAG PROTEIN; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ARTICLE; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS RESISTANCE; VIRUS STRAIN;

DRUG RESISTANCE, MULTIPLE, VIRAL; EVOLUTION, MOLECULAR; GENE PRODUCTS, GAG; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; NELFINAVIR; TREATMENT FAILURE;

EID: 33646028218     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000202650.03279.69     Document Type: Article

References (9)

1. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society - USA panel. Clin Infect Dis 2003; 37:113-128.
2. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2:760-766.
3. Mellors JW, Palmer S, Nissley D, Kearney M, Halvas E, Bixby C, et al. Low frequency non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant variants contribute to failure of efavirenz-containing regimens in NNRTI-experienced patients with negative standard genotypes for NNRTI mutations. In: 12th International HIV Drug Resistance Workshop. Los Cabos, Mexico, 10-14 June 2003 [Abstract 134].
4. Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, et al. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 2002; 76:7398-7406.
5. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998; 72:7632-7637.
6. Charpentier C, Dwyer DE, Mammano F, Lecossier D, Clavel F, Hance AJ. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol 2004; 78:4234-4247.
7. Marcelin AG, Affolabi D, Lamotte C, Mohand HA, Delaugerre C, Wirden M, et al. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. J Med Virol 2004; 74:16-20.
8. Sugiura W, Matsuda Z, Yokomaku Y, Hertogs K, Larder B, Oishi T, et al. Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2002; 46:708-715.
9. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920-928.